Premium
Mitomycin C‐loaded microcapsules in the treatment of colorectal liver metastases. Pharmacokinetics of regionally administered particulate chemotherapy
Author(s) -
Goldberg Jacqueline A.,
Pettit Lynda,
McArdle Colin S.,
Kerr David J.,
Blackie Robert,
Whately Tony L.,
Kato Tetsuro
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910215)67:4<952::aid-cncr2820670416>3.0.co;2-w
Subject(s) - mitomycin c , medicine , pharmacokinetics , distribution (mathematics) , volume of distribution , chemotherapy , drug , pharmacology , toxicity , urology , gastroenterology , surgery , mathematical analysis , mathematics
Microencapsulated mitomycin C has been used for the treatment of intrahepatic tumors in Japan, but there have been no reports of its use in western countries. In this study, the pharmacokinetic profile of intrahepatic arterial mitomycin C microcapsules is reported. Regional mitomycin C was administered to six patients, both in the microencapsulated form and in solution. The clearance (140 ± 31 1/hour, mean ± SD) and half‐life of drug in plasma (0.39 ± 0.03 hours), and volume distribution (246 ± 23 1) were significantly higher, and peak drug concentrations (80 ± 75 ng/ml) significantly lower with the microencapsulated preparation than with the free drug (clearance, 46 ± 8 1/hour; half‐life, 0.11 ± 0.02 hours; volume distribution, 33 ± 4; peak drug concentration, 812 ± 423 ng/ml), on Student's t testing ( P < 0.05). The results show that very little systemic exposure is associated with the microencapsulated form of mitomycin C. Dose escalation should be feasible without increasing systemic toxicity.